COVID19

Goodfood to Report Fourth Quarter and Fiscal Year 2022 Results

Retrieved on: 
Friday, November 18, 2022
COVID-19, Growth, Quality control, COVID19, Climate change, Transport, Legislation, Health insurance coverage in the United States, SEDAR, Risk, Intellectual property, Food industry, Risk management

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.

Key Points: 
  • This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • Such forward-looking information includes, but is not limited to, information with respect to our objectives and the strategies to achieve these objectives, as well as information with respect to our beliefs, plans, expectations, anticipations, estimates and intentions.
  • Although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, readers are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information.
  • Certain assumptions were made in preparing the forward-looking information concerning the availability of capital resources, business performance, market conditions, and customer demand.

Digihost Reports Positive Third Quarter 2022 Results

Retrieved on: 
Tuesday, November 15, 2022
Bitcoin, Growth, Public Service Commission, COVID19, TSX Venture Exchange, Policy, ATM, News, Mining, BTC, New York Public Service Commission, Documentation, Acquisition, Renewable energy, Cryptocurrency

TORONTO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Digihost Technology Inc. (“Digihost” or the “Company”) (Nasdaq: DGHI; TSXV: DGHI), an innovative U.S. based Bitcoin (“BTC”) mining company, announces unaudited financial results for the third quarter ended September 30, 2022 (all amounts in U.S. dollars, unless otherwise indicated).

Key Points: 
  • When combined with Digihosts current operations total computing capacity from the Companys New York State (NY) operations is projected to be approximately 1.7 EH.
  • Phase 1, scheduled for completion in Q4 of 2022, will provide the Company with 22 MW of power capacity resulting in additional mining capacity of approximately 550 PH.
  • Digihost is a growth-oriented blockchain technology company primarily focused on BTC mining.
  • The Company has also assumed that no significant events occur outside of the Company's normal course of business.

Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern

Retrieved on: 
Monday, November 14, 2022
CMS, Diagnosis, Esophageal cancer, EBITDA, Comerica, COVID19, MicroRNA, Thyroid cancer, DSO, Risk, CEP, Pancreatic cancer, Safety, Pancreatic cyst, Physician, Sumathi Best Television Current Reporting Award, Nine Months, Security (finance), Lung cancer, Prognosis, Sale, Cancer, Franciscan Ceramics, Broad, Continuous operation, Borrowing base, Video game, Pharmaceutical industry, Iron ore, Pharma

Third quarter Net Revenue was $8.2 million, a 2% increase as compared to the same period of 2021.

Key Points: 
  • Third quarter Net Revenue was $8.2 million, a 2% increase as compared to the same period of 2021.
  • Our loss from continuing operations in the third quarter of 2022 was $1.3 million, slightly better than the prior year quarter.
  • We are very pleased with the improvement in liquidity resulting from the sale of the Pharma business in August, stated Tom Burnell, Ph.D., President and CEO of Interpace Biosciences.
  • However, the ThyGeNEXT pricing change impacted revenue and EBITDA by approximately $1.4 million for the third quarter of 2022, stated Mr. Burnell.

Military Drones Global Market Report 2022: Increased Military Funding from Governments Worldwide Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 17, 2022
Military, Defense, MALE, SUAV, Plant, HALE, United States Department of Defense, COVID19, Government, Food industry, VA-215 (U.S. Navy), UCAV, United States Army, Army

The "Military Drones Global Market Report 2022, By Drone Type, Type, Technology, Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Military Drones Global Market Report 2022, By Drone Type, Type, Technology, Application" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in the global military drones market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • Increasing government funding on military drones to enhance efficiency in military operations boosts the demand for the production of military drones.
  • Drone swarm technology is growing its popularity in the military drones market due to its cost efficiency and high fire-power.

Medica Foundation supports the expansion of equitable pediatric mobile care to underserved families across the region.

Retrieved on: 
Monday, November 14, 2022
Professional Services, Pharmaceutical, Family, Philanthropy, Consumer, Hospitals, Health Insurance, Foundation, Children, Insurance, Other Philanthropy, Health, Head, Medicaid, Food, COVID19, Minneapolis–Saint Paul, Vaccination, Medicare, Housing, Public health, Heart, Supreme court, School, Esther Tomljanovich, Trauma, Patient, Vaccine, Health insurance, Pharmaceutical industry, Medicine, HCMC

Recognizing this innovative way to serve our diverse communities across the Twin Cities, the Medica Foundation has awarded their prestigious 2022 Esther Tomljanovich Strategic Initiative grant to Hennepin Healthcares Pediatric Mobile Health.

Key Points: 
  • Recognizing this innovative way to serve our diverse communities across the Twin Cities, the Medica Foundation has awarded their prestigious 2022 Esther Tomljanovich Strategic Initiative grant to Hennepin Healthcares Pediatric Mobile Health.
  • Pediatric Mobile Health is an innovative solution that meets children and families where they are to provide preventive care and immunizations, which is at the heart of what we do at the Medica Foundation, said JoAnn Birkholz, Executive Director of the Medica Foundation.
  • The $200,000 investment will support the expansion of their Pediatric Mobile Health to reach children and families in schools, at Head Start programs, and even contribute resources for food and housing assistance.
  • The Medica Foundation was one of the projects initial funders previously awarding $50,000 over the last two years specifically addressing vaccination needs.

World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China.

Retrieved on: 
Thursday, November 24, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Research, Science, Pharmaceutical, Safety, Public health, Convidecia, VLP, Pain, International Society, CanSino Biologics, National Medical Products Administration, Research, Ageing, Tidal volume, Multimedia, Noble gas, Atmosphere of Earth, Chronic obstructive pulmonary disease, COVID-19, Partnership, Severe acute respiratory syndrome coronavirus 2, McGrath, Adenoviridae, Vaccine, Nassar Ikram, WHO, News, Enterprise Ireland, Mechanical, Mechanical ventilation, Vaccination, Use, Effect, Growth, DOI, Diagnosis, Inhalation, COPD, Medtech, Ventilation, Patient, Global Initiative, HKEX, McLoughlin, SSE, COVID19, Pharmaceutical industry, Medical device, Lancet, Medicine

This route mimics the natural infection pathway of the respiratory virus COVID-19 and may create additional benefits through generating mucosal immunity.

Key Points: 
  • This route mimics the natural infection pathway of the respiratory virus COVID-19 and may create additional benefits through generating mucosal immunity.
  • 2,3
    Further clinical trials of the inhaled vaccine are progressing in Asia and Latin America to support other country approvals for this innovative technology.
  • John Power, Aerogen CEO & Founder said The world has an urgent need for an effective, low-cost, globally scalable, and globally accessible solution to mass vaccination.
  • We are delighted with the news of approval and public rollout in China and look forward to further approval of inhaled vaccines around the world.

CONSILIUM STAFFING CHRONICLES MILESTONES AND BUSINESS GROWTH OF 2022

Retrieved on: 
Friday, November 18, 2022
Geographic Locator Codes, Growth, Consilium, Physician, Healthcare Facilities Accreditation Program, Practitioner, COVID19, Renewable energy, Industrial design, Medicine

DALLAS, Nov. 17, 2022 /PRNewswire/ -- Consilium Staffing , a locum tenens firm with more than a decade of award-winning experience in the healthcare staffing industry, announced that 2022 was a record-breaking year for growth and expansionand the upward business trajectory is expected to continue in 2023.

Key Points: 
  • DALLAS, Nov. 17, 2022 /PRNewswire/ -- Consilium Staffing , a locum tenens firm with more than a decade of award-winning experience in the healthcare staffing industry, announced that 2022 was a record-breaking year for growth and expansionand the upward business trajectory is expected to continue in 2023.
  • Consilium's Executive Vice President Matthew Baade explained that the company is projected to finish 2022 with better than 30% year-over-year growth.
  • The following year (2021), Consilium grew by another 19%, amounting to roughly 40% growth over two years.
  • Consilium is a locum tenens firm with more than a decade of award-winning experience in the healthcare staffing industry.

Treasury Board President Mona Fortier tables the Supplementary Estimates (B), 2022-23

Retrieved on: 
Thursday, November 17, 2022
Transfer, Treasury Board of Canada, Canada Health Transfer, Estimates, Canadian House of Commons Standing Committee on Government Operations and Estimates, House, Refugee, Indigenous Services Canada, Commons, Housing, Treasury, Treasury Board Secretariat (Ontario), Investment, COVID19, Government, Health insurance

OTTAWA, ON, Nov. 17, 2022 /CNW/ - Today, the Honourable Mona Fortier, President of the Treasury Board of Canada, tabled the Supplementary Estimates (B), 202223, in the House of Commons.

Key Points: 
  • OTTAWA, ON, Nov. 17, 2022 /CNW/ - Today, the Honourable Mona Fortier, President of the Treasury Board of Canada, tabled the Supplementary Estimates (B), 202223, in the House of Commons.
  • These Supplementary Estimates propose $20.8 billion in voted budgetary spending across 87 federal organizations.
  • - The Honourable Mona Fortier, President of the Treasury Board
    The 202223 Main Estimates, requested authority to spend $190.3billion in voted budgetary expenditures.
  • Total spending in these Supplementary Estimates represents a 10.4%increase to planned budgetary voted spending over the 202223 Estimates to date.

Bioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-print

Retrieved on: 
Wednesday, November 16, 2022
Preprint, Workplace, Technology, COVID, OTCQB, PCR, Nuclear magnetic resonance, Population, Knowledge, Carbohydrate, Pulmonary fibrosis, Galectin, Safety, Degenerative disease, Ventilation, Virology, Hypoxia, SAE, NMR, Patient, Mask, COVID-19, COVID19, Virus, Clinical trial, Stroke, Immune system, Science, Vaccine, Disease, Viral load, Pharmaceutical industry, Long COVID

BOSTON, Nov. 16, 2022 /PRNewswire/ -- BIOXYTRAN, INC. (OTCQB: BIXT), (the "Company"), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced positive topline safety and efficacy results of its randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19.  During the 7 days of treatment, an orally administered Galectin Antagonist in the form of a chewable tablet was administered 8 times per day on an hourly basis. The endpoint was a statistically significant reduction in viral load measured by the number of patients reaching a below threshold PCR value (Ct value ≥ 29) by day 7.  The trial met its endpoint with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant (p-value = .001).  Our analysis also revealed an 88% response rate by day 3, which was statistically significant (p-value = .001). There were no drug-related serious adverse events (SAE's) in the patient population or viral rebounds by day 14 in the patient population. The positive data from this clinical trial provided the rationale of dosing and protocol design for study in an upcoming phase 2/3 registrational trial. 

Key Points: 
  • There were no drug-related serious adverse events (SAE's) in the patient population or viral rebounds by day 14 in the patient population.
  • The positive data from this clinical trial provided the rationale of dosing and protocol design for study in an upcoming phase 2/3 registrational trial.
  • Nuclear Magnetic Resonance ("NMR") testing was used to elucidate the Mechanism of Action of the specific Galectin Antagonist.
  • While the Galectin Antagonist does indeed bind to the S1 Spike Protein, the study showed that it could bind in 2 different orientations with galectin-3.

Omdia research finds display demand expected to rebound in 2023

Retrieved on: 
Tuesday, November 8, 2022
Organization, Yoy, OLED, Major, Television, OLED TV, View, History, Display, Efficiency, Research, Multimedia, Technology, COVID19, Renewable energy

With softened inflation and slowing interest rate hikes, plummeting demand has bottomed out, thereby making way for a rebound to normalization in demand by the second half of 2023.

Key Points: 
  • With softened inflation and slowing interest rate hikes, plummeting demand has bottomed out, thereby making way for a rebound to normalization in demand by the second half of 2023.
  • Display demand in 2022 was expected to fall below the normal level and escape the impact of COVID19.
  • TV display takes around 80% area shipment of total flat panel display, TV display demand recovery influence total flat display area demand forecast.
  • This is expected to remain a burden on the panel demand market in the first half of 2023.